Nitin Agarwal
University of Pittsburgh
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nitin Agarwal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06973109 · Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery OutcomesUniversity of Pittsburgh · withdrawn · Osteoporosis, Post-menopausal · principal investigator
- N/ANCT06704919 · Conduit Cages and Fibergraft BG PuttyUniversity of Pittsburgh · terminated · Degenerative Disc Disease, Herniated Disc · principal investigator
- N/ANCT06704906 · Adult Patient Outcomes After Spine Surgery With Fibergraft BG Putty/Viper PrimeUniversity of Pittsburgh · terminated · Spondylolisthesis, Lumbar Region, Spinal Trauma With Neurological Deficit, Degeneration of Lumbar Intervertebral Disc · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Wireless Metamaterial Interbody Cage for Real-Time Assessment of Lumbar Spinal Fusion In VivoR21AR085218 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2025 to 2026 · $183,975 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:51 UTC. The ranking covers the 200 most relevant of 190 PubMed records, and a shared surname and initials can bring in a namesake. All 190 on PubMed
- Olaparib for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 20201,923 citationsRCR 83.2
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.N Engl J Med · 20191,279 citationsRCR 51.3
- 1,256 citationsRCR 33.8
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.Lancet Oncol · 2016767 citationsRCR 24.3
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.N Engl J Med · 2020675 citationsRCR 25.8
- 480 citationsRCR 26.5
- 470 citationsRCR 39.6
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.J Clin Oncol · 2021455 citationsRCR 26.3
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.J Clin Oncol · 2016251 citationsRCR 8.0
- 250 citationsRCR 7.1